The investigation did not identify a product problem.The cause of the event could not be determined.As the roche elecsys results were repeatable, the most likely cause was that the unknown competitor method measures the novorapid insulin (insulin aspart, genetically engineered human insulin analogon) taken by the patient which is not recognized by the elecsys insulin assay.
|
The initial reporter received questionable elecsys insulin results for one patient tested on a cobas 8000 e601 module serial number (b)(4).On (b)(6) 2022, the initial insulin result was 0.200 u/ml, and it was accompanied by a data flag.The repeat result was 0.221 u/ml.On (b)(6) 2022, the repeat result performed on a competitor instrument (chemiluminescence instrument) was 118 mu/l.On (b)(6) 2022, the repeated result was performed on the cobas 8000 e601 module and the result was 0.343 u/ml and 0.310 u/ml.On (b)(6) 2022, the repeated result was performed on the cobas 8000 e601 module and the result was 1.15 u/ml, with a dilution ratio of 2:1.The questionable results were reported outside the laboratory.
|